[New therapeutic trends in thalassemia: oral chelating agents].

Abstract

The future therapeutic strategy for decreasing iron overload in poly-transfused patients will include oral chelation. The product currently undergoing the most intensive experimentation is Ll (1,2-dimethyl-3-hydroxypyrid-4-one). We report here a short-term efficacy study carried out in 10 thalassemic transfusion-dependent pediatric volunteer patients, already closely followed in our Day Hospital, after having provided their informed consent. In our study Ll, when compared to Desferrioxamine, was clearly efficacious and safe.

• Authors: V Carnelli, S Terzoli, G Fossati, G Careddu, M Perri, L Pedrotti, N Mirra
• Journal: La Pediatria medica e chirurgica : Medical and surgical pediatrics (Pediatr Med Chir) 1992 May-Jun Vol. 14 Issue 3 Pg. 273-5 ISSN: 0391-5387 [Print] Italy
• Vernacular Title: Nuove prospettive terapeutiche per la thalassemia: i chelanti orali.
• PMID: 1528794 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Iron Chelating Agents
• Pyridones
• Deferiprone
• Deferoxamine

Topics

• Administration, Oral
• Adolescent
• Adult
• Child
• Deferiprone
• Deferoxamine (therapeutic use)
• Female
• Humans
• Informed Consent
• Iron Chelating Agents (therapeutic use)
• Male
• Pyridones (administration & dosage)
• Thalassemia (drug therapy)